

**Formal Consultative Meeting of the States Parties  
to the Convention on the Prohibition of the  
Development, Production and Stockpiling  
of Bacteriological (Biological) and  
Toxin Weapons and on Their Destruction**

Distr.: General  
6 September 2022

English only

---

2022 Meeting

Geneva, 26 August and 5-9 September 2022

Item 6 of the agenda

**Respective outstanding questions by the Russian Federation  
to the United States and to Ukraine concerning the fulfilment  
of their respective obligations under the Convention in the context  
of the operation of biological laboratories in Ukraine**

**Questions to Ukraine regarding compliance with  
obligations under Part 2 of Article I of the  
Convention on the Prohibition of the Development,  
Production and Stockpiling of Bacteriological  
(Biological) and Toxin Weapons and on Their  
Destruction (BTWC), in the context of activities of  
biological laboratories**

**Submitted by the Russian Federation**



## UP-4 : Risk assessment of selected Especially Dangerous Pathogens potentially carried by migratory birds over Ukraine



BTRP TO 04 Ukraine Phase IIb – Country Science Plan  
CDRL A017, Rev. 06 / June 2019

### VII. CURRENT PROJECTS

Key aspects of each CBR project are outlined below.

#### A. UP-4 Option Year (OY)2: Risk assessment of selected Especially Dangerous Pathogens potentially carried by migratory birds over Ukraine

- **Purpose:** Comprised of a base year and two option years (OY1 and 2), the UP-4 research project aims to assess the ecologic, epizootic, and epidemiologic risk of infectious diseases transmitted by migratory birds associated with major flyways in Ukraine.
- **Engaged:** University of Alaska Anchorage (UAA)
- **Primary Collaborators:**
  - Dr. Eric Bortz, Assistant Professor, Dept. of Biological Sciences, UAA, Anchorage, AK, USA
- **Reginal Partners:**
  - Dr. Otar Parkadze, Director (Avian Diseases), Laboratory of the Ministry of Agriculture, Tbilisi, Georgia
  - Dr. Levan Ninua, Research associate, Institute of Ecology, Iliia State University, Tbilisi, Georgia
- **Ukrainian Collaborating Institutes:**
  - National Scientific Center "Institute of the Experimental and Clinical Veterinary Medicine" (NSC IECVM), Kharkiv, Ukraine
  - State Scientific Research Institute of Laboratory Diagnostics and Veterinary and Sanitary Expertise (SSRILDVSE), Kyiv, Ukraine
  - Institute of Veterinary Medicine (IVM), Kyiv, Ukraine
  - SI (State Institution) "Ukrainian I. Mechnikov Anti-Plague Research Institute" (UAPRI) of the Ministry of Health of Ukraine, Odessa, Ukraine
- **Primary Ukrainian Collaborators:**
  - Dr. Borys Stegnyy (NSC IECVM): Ukraine Project Manager
  - Dr. Anton Gerylovych (NSC IECVM): Ukraine Leader on Molecular Epidemiology
  - Dr. Denys Muzyka (NSC IECVM): Ukraine Leader on Field Collection
  - Dr. Andrii Merzhenskyi (SSRILDVSE): Participating Institution Manager
  - Dr. Sergiy Nychyk (IVM): Participating Institution Manager
  - Mr. Maksym Bezymennyi (IVM): GIS Leader
  - Dr. Oksana Yurchenko (UAPRI): Principal Investigator (TBD)
- **Regions Targeted:** Three distinct ecoregions in northern and southern Ukraine along major avian migratory flyways, including Odessa, Kherson, and Chernihiv Oblasts
- **Target Pathogens:** Avian EDPs (AIV, HPAIV, and NDV)
- **Field Collection Activities:** In selected regions of Ukraine, bird specimens will be collected in field expeditions according to the field schedule organized by NSC IECVM, closely mirroring the fieldwork activities in the UP-4 base year and OY1. Sampling will be organized to include ornithological observations recorded in an



Page 16 of 63

Purpose: Comprised of a base year and two option years (OY1 and 2), the UP-4 research project aims to assess the ecologic, epizootic, and epidemiologic risk of infectious diseases transmitted by migratory birds associated with major flyways in Ukraine.

Wild ducks' migration routes from the South of Ukraine to Russia based on GPS tracking

During their spring migration a part of the birds migrated to the North-East. The maximum distance – 2000 km., some birds covered the distance in 3-4 days.  
During the nidification the birds were in Russia.



## UP-8: Prevalence of Crimean Congo hemorrhagic fever virus and hantaviruses in Ukraine and the potential requirement for differential diagnosis of suspect leptospirosis patients

### B. UP-8 OY1: Prevalence of Crimean Congo hemorrhagic fever virus and hantaviruses in Ukraine and the potential requirement for differential diagnosis of suspect leptospirosis patients

- Purpose:** To determine the potential threat of Crimean Congo hemorrhagic fever virus (CCHFV) and hantaviruses, which are high priority pathogens that cause, often severe, febrile illnesses and are believed to be circulating in Ukraine but are not effectively detected or diagnosed.
- Engaged:** University of Tennessee Health Sciences Center (UTHSC), University of Florida (UOF), University of New Mexico (UNM), and Labyrinth Global Health, Inc.
- Primary Collaborators:**
  - Dr. Colleen B. Jonsson, Professor, UTHSC, Memphis, TN USA
  - Dr. Gregory E. Glass, Professor, UOF, Gainesville, FL, USA
  - Dr. Gregory J. Mertz, MD, UNM, Albuquerque, NM, USA
- Ukrainian Collaborating Institutes:**
  - State Institution Public Health Center of the Ministry of Health of Ukraine (PHC)
  - State Institution Volyn' Oblast Laboratory Center of the Ministry of Health of Ukraine (VOLC)
  - State Institution Lviv Oblast Laboratory Center of the Ministry of Health of Ukraine (LOLC)
  - State Institution Zakarpattia Oblast Laboratory Center of the Ministry of Health of Ukraine (ZOLC)
  - State Institution Dnipropetrovsk Oblast Laboratory Center of the Ministry of Health of Ukraine
- Primary Ukrainian Collaborators:**
  - Dr. Iryna Demchyshyna (PHC): Ukraine Project Manager and Science Leader on testing samples to be collected in the project (rodent and tick samples, as well as human samples from hospitalized patients)
  - Dr. Ihor Nebogatkin (PHC): Ukraine Lead on environmental sampling efforts
  - Dr. Oksana Semenyshyn (Lviv OLC): Lead on human sample processing at Lviv OLC
  - Dr. Nataliia Yanko (Volyn OLC): Lead on organization of field efforts in Volyn Oblast
  - Dr. Serhiy Lystovka (MoD): Ukraine Project Manager for MoD-related efforts
- Regions Targeted:** In OY1, project collaborators plan to analyze environmental samples (ticks) and rodents from routine collections made by OLC laboratories and expand activities to surveillance of hospital patients in Kyiv and Lviv for the potential misdiagnosis of hemorrhagic fever diseases, while also conducting a seroprevalence study of healthy soldiers from four regions of Ukraine: Lviv, Kharkiv, Odessa, and Kyiv.
- Target Pathogens:** CCHFV and hantaviruses, with primary focus on Dobrava virus (DOBV) and Puumala virus (PUUV)

A decision signed by the head of the Center for Public Health's ethics committee on June 12, 2019, in the framework of the project UP-8.

**Purpose:** To determine the potential threat of Crimean Congo hemorrhagic fever virus (CCHFV) and hantaviruses, which are high priority pathogens that cause, often severe, febrile illnesses and are believed to be circulating in Ukraine but are not effectively detected or diagnosed.

«...minor incidents involving volunteers are supposed to be reported to bioethics committees of the US and Ukraine within 72 hours, while serious accidents, involving the subjects' death are to be reported within 24 hours...»

**Target Pathogens:** CCHFV and hantaviruses, with primary focus on Dobrava virus (DOBV) and Puumala virus (PUUV)

Розповсюдження вірусу Крим-Конго геморагічної гарячки (вірус ККГГ) і хантавірусів в Україні та потенційна потреба диференційної діагностики у пацієнтів з підозрою на лептоспіроз

- Дослідження прийматиме Міністерство оборони США, інша регуляторна структура уряду США або будь-який регуляторний орган в Україні.

Якщо учасник вирішує відмовитися від участі в дослідженні або висходити із нього, будь-які зібрані в ході дослідження дані, включаючи зразки для лабораторних досліджень, будуть вилучені з аналізу та знищені.

### 3.5. Процедура на випадок відхилення від протоколу

Весь медичний персонал, що проводить відбір зразків крові та персонал лабораторій Служби превентивної медицини МО України, який бере участь у лабораторних процесах, до початку дослідження проведуть навчання з процедур та етики проведення досліджень, суб'єктом якого є людина. У разі ненавмисного вкlopenня осіб, що не відповідають критеріям вкlopenня, біологічні зразки від них не повинні відбиратися, будь-які зібрані мають бути вилучені з аналізу та знищені, а особа має бути проінформована про це. Якщо зразки для лабораторних досліджень від осіб, що не відповідають критеріям вкlopenня, вже були відібрані, вони будуть вилучені, а особа – проінформована про це.

У цілому, про відхилення від протоколу, що не впливають на здоров'я учасників, буде повідомлено під час поточного перегляду протоколу та/або в остаточному звіті. Про відхилення від протоколу або неочікувані ситуації, що можуть вплинути на здоров'я, безпеку або благополуччя учасників дослідження, буде негайно повідомлено головному досліднику / менеджеру збору даних, українському комітету з біоетики та Агентству

зменшення загрози Міністерства оборони США (А33). Про незначні інциденти слід повідомляти протягом 72 годин, а про серйозні, включаючи випадки смерті – протягом 24 годин. Усі випадки смерті суб'єктів дослідження, підозрювані або відомі як такі, що пов'язані з процедурами дослідження, повинні бути доведені до відома комітетів із біоетики в США та Україні. Про будь-які відхилення від протоколу або неочікувані ситуації, які викликають занепокоєння щодо наукової обґрунтованості продовження дослідження, також буде негайно повідомлено головному досліднику, головному співдосліднику, українському комітету з біоетики та А33.


Якщо очікується відхилення від протоколу, головний дослідник та головний співдослідник попередять комітет з біоетики в Україні, а також зажадають записати дозвіл на вилучення з протоколу у А33. Усі зміни в протоколі та згоди повинні бути схвалені комітетами з біоетики в Україні до початку їх впровадження.







# UP-1 re-scoped to project UP-6: Ecological and epidemiological evaluation to establish the prevalence of natural focal infections caused by *Rickettsia* spp. and *Coxiella burnetii* in different landscape zones of Ukraine





BTRP TO 04 Ukraine Phase IIb – Country Science Plan  
CDRL A017, Rev. 06 / June 2019

**X. CLOSED PROJECTS**

To date, two project proposals have been officially closed. Key aspects of the proposed studies are provided below.

**A. UP-1 re-scoped to project UP-6: Ecological and epidemiological evaluation to establish the prevalence of natural focal infections caused by *Rickettsia* spp. and *Coxiella burnetii* in different landscape zones of Ukraine**

- Purpose:** To conduct molecular and serological analyses that investigate rickettsial and *C. burnetii* pathogens transmitted by arthropods within ecologically distinct locations.
- Engaged:** CDC and the NMRC
- Primary Collaborators:**
  - Dr. William Nicholson (CDC): US Co-Lead Investigator
  - Dr. Allen Richards (Naval Medical Research Center, NMRC): US Co-Lead Investigator
- Ukrainian Institutes:** SSRILDVSE, IVM, UAPRI, LRIEH, Regional State Laboratories of Veterinary Medicine (RSLVMs)
- Primary Ukrainian Collaborators:**
  - Dr. Oleg Nevolko (SSRILDVSE), Ukraine Project Manager
  - Dr. Serhiy Nychyk (IVM), Participating Institution Manager
  - Dr. Liudmila Maruschak (SSRILDVSE), Ukraine PCR Leader
  - Dr. Olena Yegorova (UAPRI), Participating Institution Manager
  - Dr. Ihor Lozynskyi (LRIEH), Participating Institution Manager
- Regions Targeted:** Lviv Oblast (the forest-steppe zone), Odessa Oblast (steppe zone), and Zakarpattia oblast (mountain zone).
- Field Collection Activities:** Tick and ruminant collection activities, with at least three 7-day field trips per year (spring, summer, and fall) during all years of the project.
- Direct Cost:** \$2,461,994
- Project Length and Aims:** With a proposed 3-year period of performance, the first year aimed to provide training in study techniques and to initiate field collection activities. The subsequent 2 years focused on environmental assessment employing GIS, PCR, ELISA, and IFA technology. The project would achieve BTRP objectives through execution of the following Aims.
  - AIM 1. Analysis of pathogen antibody prevalence in healthy Ukrainians:**
    - Task 1.1. Titrate rickettsial antibodies in ELISA positive samples (TGR, SFGR, *C. burnetii*) identified during the project development grant (PDG)
    - Task 1.2. Conduct serosurveys in human populations in the selected regions of Ukraine.
    - Task 1.3. Confirm by indirect IFA the samples that test positive by ELISA for antibodies specific to TGR, SFGR, and *C. burnetii* (for both previously and newly collected samples).





Page 48 of 63

Partner project agreement STCU P364/ DTRA UP-2 between U.S. Department of Defence Threat Reduction Agency/Biological Threat Reduction Project, the Science and Technology Center in Ukraine and Central Sanitary Epidemiological Station Lviv Research Institute of Epidemiology and Hygiene, Ukrainian Research Anti-Plague Institute Ministry of Health of Ukraine, Central Sanitary Epidemiological Station Ministry of Health of Ukraine

**Purpose:** To conduct molecular and serological analyses that investigate rickettsial and *C. burnetii* pathogens transmitted by arthropods within ecologically distinct locations.  
**Engaged:** CDC and the NMRC (Naval Medical Research Center)

**Field Collection Activities:** Ticks and small mammals were collected 2X per year in 2012-2013 within regions targeted by the project



STCU P364/ DTRA UP-2

**PARTNER PROJECT AGREEMENT STCU P364/ DTRA UP-2**

between  
U.S. Department of Defense Threat Reduction Agency/Biological Threat Reduction Project,  
the Science and Technology Center in Ukraine  
and  
Lviv Research Institute of Epidemiology and Hygiene  
Ukrainian Research Anti-Plague Institute Ministry of Health of Ukraine  
Central Sanitary Epidemiological Station Ministry of Health of Ukraine

Operative Commencement Date: 1 November 2012

**Article 10. Dispute**

Disputes arising from the performance of the Agreement shall be resolved by the Arbitration Panel established by the Parties to the Agreement.

**Article 11. Suspension and Termination of the Agreement**

The Parties agree that the Agreement shall be suspended or terminated in the event of a breach of the Agreement by either Party.

**Article 12. Amendments, Variations, or Additions**

The Parties agree that any amendments, variations, or additions to the Agreement shall be made in writing and signed by both Parties.

**Article 13. Annexes**

The Annexes to the Agreement shall be considered an integral part of the Agreement.



STCU P364/ DTRA UP-2

**Article 14. Signatures**

The Parties agree that the Agreement shall be signed by the authorized representatives of both Parties.

**Article 15. Final Provisions**

The Parties agree that the Agreement shall be entered into as of the date of the last signature.

**Article 16. Entire Agreement**

The Agreement shall constitute the entire agreement between the Parties.

**Article 17. Governing Law**

The Agreement shall be governed by the laws of the United States of America.

**Article 18. Force Majeure**

The Parties agree that the Agreement shall be terminated in the event of a force majeure event.

**Article 19. Notices**

Notices shall be given in writing to the Parties at the addresses set forth in the Annexes.

**Article 20. Assignment**

The Parties agree that the Agreement shall not be assigned without the written consent of both Parties.

**Article 21. Waiver**

The Parties agree that the Agreement shall not be waived without the written consent of both Parties.

**Article 22. Severability**

If any provision of the Agreement is found to be unenforceable, the remaining provisions shall remain in effect.

**Article 23. Counterparts**


The Agreement may be executed in counterparts, each of which shall be deemed an original.

**Article 24. Binding Effect**

The Agreement shall be binding on the Parties and their successors.


**Article 25. In Witness Whereof**

The Parties have signed the Agreement in two copies, each of which shall be deemed an original.



STCU P364/ DTRA UP-2





SCIENCE AND TECHNOLOGY CENTER IN UKRAINE

**Project Agreement**

**P781**

**between**

**THE SCIENCE AND TECHNOLOGY CENTER IN UKRAINE**

**and**

**NSC Institute of Experimental and Clinical Veterinary Medicine and National Center for Disease Control and Public Health; Richard G. Lugar Center for Public Health Research**

**Kyiv**

**OPERATIVE COMMENCEMENT DATE:**

HAVE AGREED AS FOLLOWS: \_\_\_\_\_

Article 1 – Scope of agreement

1.1 The recipient entity(ies) shall carry out the work plan set forth in Annex I according to the conditions of the agreement, subject to the provisions of the STCU agreement, and the statute of the Center (hereinafter referred to as "the STCU statute") which governs in case of conflict. The activities carried out under the agreement are entitled "Risk of Emerging Infections from Insectivorous Bats in Ukraine and Georgia". (hereinafter referred to as "the project"). All Project Activities subject to this Agreement are to be executed by the Recipient, using only funding provided by the Center and/or sources approved by the Center. The recipient entity(ies) shall notify the Center immediately if it and/or other participating institutions determine at any time to utilize any other funding sources to execute such Project activities.

1.2 Subject to any amendments or exclusions by any other articles, the detailed terms of the agreement are specified in the annexes which form an integral part of the agreement. In the case of conflict between any provision in the annexes and any other provision of the agreement, the latter shall prevail.

Objectives: Detecting of emerging viral (coronaviruses, filoviruses, paramyxoviruses, orthomyxoviruses, lyssaviruses) bacterial (Brucella spp, Leptospira spp, Yersinia spp) pathogens important for human and animal health in bats in Ukraine, Georgia


Standard operating procedures for safe bat trap implementation, sampling, preparation for identification, typing, sequencing, and niche modeling; field and laboratory work

Project Agreement P781 between the STCU and NSC Institute of Experimental and Clinical Veterinary Medicine and National Center for Disease Control and Public Health; Richard G. Lugar Center for Public Health Research

P781 STCU Partner Project Proposal was adopted

Article 1. Scope of agreement  
The activities carried out under the agreement are entitled "Risk emerging infections from Insectivorous bats in Ukraine and Georgia"

UNCLASSIFIED



**Risk of Emerging Infections from Insectivorous Bats in Ukraine and Georgia.** Denys Muzyka (NSC IECVM), Lela Urushadze (NCDC) and Andres Velasco-Villa (US CDC), HDTRA1-14-24-FRCWMD-BAA

**Objectives:** Detecting of emerging viral (coronaviruses, filoviruses, paramyxoviruses, orthomyxoviruses, lyssaviruses) bacterial (Brucella spp, Leptospira spp, Yersinia spp) pathogens important for human and animal health in bats in Ukraine, Georgia; investigating how landscape biodiversity changes influence the relative composition of endemic viral and bacterial agents in bat populations, as well as assess their eco-evolutionary linkages with disease emergence in humans and domestic animals. Build a sustainable harmonized surveillance network for the early detection, full genomic characterization of high consequence agents associated with bat populations in Ukraine, Georgia.

**Method:** Integration of a multidisciplinary, interagency coalition of premier public health, veterinary institutions and Universities to foster the creation of a regional, self sustainable multinational coalition for the early detection, typing, development of a high-level analytical framework to provide adequate interpretation of findings.

**Status of effort:** This proposal will be conducted and integrated by a coordinated persistent effort of principal investigators from NSC IECVM, NCDC, US CDC in collaboration with Virginia Tech and USGS. Expected findings are of interest for the fields of ecology, evolution of infectious bacterial and viral diseases, early warning systems, and global human and animals health.

**Personnel Supported:** More than 60 scientists from USA, Ukraine, Georgia with either PhD, Master graduate and/or undergraduate degrees with more than 10 years of experience will participate on field activity, diagnostics, molecular typing, Sanger sequencing, next generation sequencing, bio-informatics, ecology niche modeling, data visualization.

**Publications & Meetings:** We anticipate active participation in at least one peer-reviewed scientific publications and participation two scientific meetings at year.

**Y1. SOPs implementation for biosecure bat capture, sampling, processing for detection, typing, sequencing, niche modeling, field and laboratory activity. Y2. Continuing field and laboratory activity; development of analytical pipelines for comparative genomics and ecological niche modeling. QAI/QC implementation algorithms and trouble shooting. Y3. Sustainability assessment and implementation completion phase, final data analyses, data visualizations, presentation of future directions.**

**Funding:** Y020-2022 Total Ukraine-Georgia \$1600K/year: \$207-398K/year IECVM, \$178-257K/year NCDC, \$53K/year STCU. Total CDC coalition \$1,554,519/3 years: \$512K-527K/year.

**Contact information:** Dr. D. Muzyka, dmuzyka77@gmail.com, +380673895798; Dr. L. Urushadze, lelnote@gmail.com, +995992045434; Dr. Andres Velasco-Villa, av20@rockwell-stc.com, +1408 260 0000

UNCLASSIFIED

STCU PARTNER PROJECT PROPOSAL P781

1. Title of Project: Risk of Emerging Infections from Insectivorous Bats in Ukraine and Georgia

2. Partner(s) carrying out the project in project agreement: (Name, Institution, POC, Email, Telephone, Address)

3. Project Manager: (Name, Institution, POC, Email, Telephone, Address)

4. Project Description: (Detailed description of the project, its objectives, and the expected outcomes)

5. Project Budget: (Detailed budget breakdown, including personnel, materials, travel, and other costs)

6. Project Timeline: (Detailed timeline of the project, including start and end dates, and key milestones)

7. Project Evaluation: (Detailed evaluation plan, including key performance indicators and assessment methods)

8. Project Reporting: (Detailed reporting requirements, including frequency and format of reports)

9. Project Termination: (Detailed termination plan, including conditions for termination and responsibilities)

10. Project Signatures: (Signatures of all parties involved in the project agreement)

PARTICIPATING INSTITUTION CONCURRENCE P781

1. I, the undersigned, agree to participate in the project "Risk of Emerging Infections from Insectivorous Bats in Ukraine and Georgia".

2. I agree to provide the necessary resources and support for the project, as outlined in the project agreement.

3. I agree to follow the project timeline and reporting requirements, as outlined in the project agreement.

4. I agree to participate in the project evaluation and reporting, as outlined in the project agreement.

5. I agree to terminate the project in accordance with the project agreement.

6. I agree to sign and submit this concurrence form to the project manager.

7. I agree to provide my signature and stamp to the project manager.

8. I agree to provide my contact information to the project manager.

9. I agree to provide my institutional affiliation to the project manager.

10. I agree to provide my institutional address to the project manager.

11. I agree to provide my institutional telephone number to the project manager.

12. I agree to provide my institutional email address to the project manager.

13. I agree to provide my institutional website to the project manager.

14. I agree to provide my institutional logo to the project manager.

15. I agree to provide my institutional seal to the project manager.

16. I agree to provide my institutional stamp to the project manager.

17. I agree to provide my institutional signature to the project manager.

18. I agree to provide my institutional name to the project manager.

19. I agree to provide my institutional title to the project manager.

20. I agree to provide my institutional position to the project manager.

## TAP-6: Analysis of the threat of spread of African swine fever and classical swine fever in wild boar populations in Ukraine: Improving diagnosis, surveillance, and prevention

### VIII. PLANNED PROJECTS

N/A

### IX. COMPLETED PROJECTS

Key aspects of each proposed project are outlined below.

#### A. TAP-6: Analysis of the threat of spread of African swine fever and classical swine fever in wild boar populations in Ukraine: Improving diagnosis, surveillance, and prevention

- **Purpose:** To support continued surveillance and forecasting of the ASF and Classical Swine Fever (CSF) epizootic situation among wild pig populations inhabiting regions of Ukraine, which border the Russian Federation (RF), Belarus, and Poland, and to evaluate the risk of transmission to domestic pigs in the country.
- **Engaged:** Orion Integrated Biosciences, Inc. (OIB; Larchmont, NY, USA)
- **Primary Collaborators:**
  - Dr. Willy Valdivia (OIB)
- **Ukrainian Collaborating Institutes**
  - SSRILDVSE, FSCP
  - IVM, NAAS
- **Primary Ukrainian Collaborators:**
  - Dr. Oleg Nevolko (SSRILDVSE)
  - Dr. Sergiy Nychyk (IVM)
- **Region Targeted:** Administrative geographic regions chosen for these studies are Vinnytsa, Volyn', Dnipropetrovsk, Donetsk, Zhytomyr, Zakarpattia, Kyiv, Lugansk, Lviv, Odesa, Poltava, Rivne, Sumy, Kharkiv, Cherkassy, and Chernihiv Oblasts.
- **Target Pathogens:** ASF and CSF viruses
- **Field Collection Activities:** Samples were collected from wild boar during the state-specified hunting season.
- **Direct Cost: \$132,000**
- **Project Length and Aims:** 12 months (1 September 2016 – 31 August 2017)
  - **AIM 1. Sampling.**  
Collect georeferenced biological specimens (e.g., blood and organ samples, including: Spleen, lymph nodes, lungs, and kidneys) from wild boar to test for ASF and CSF.
  - **AIM 2. Laboratory Diagnostics for ASF and CSF.**  
Perform laboratory investigations, personnel training, and capacity building to improve capability for ASF and CSF diagnostics.
  - **AIM 3. Pathogen Characterization.**  
Determine pathogen diversity by sequence analysis of ASFV- or CSFV-positive specimens.

TAP-6: Analysis of the threat of spread of African swine fever and classical swine fever in wild boar populations in Ukraine: Improving diagnosis, surveillance, and prevention

**Purpose:** To support continued surveillance and forecasting of the ASF and Classical Swine Fever (CSF) epizootic situation among wild pig populations inhabiting **regions of Ukraine, which border the Russian Federation, Belarus, and Poland**, and to evaluate the risk of transmission to domestic pigs in the country.



- **AIM 4. Genomic-Based Biosurveillance and Data Analysis.**  
Utilize genomic-based biosurveillance technologies to analyze and map project-acquired data and to generate situational awareness reports.
- **AIM 5. Training and Reporting.**  
Conduct training, develop training materials, and present scientific findings.
- **Period of Performance:** 1 September 2016 – 31 August 2017
- **Summary:** TAP-6 focused on laboratory diagnostic studies to assess the risk of transboundary transfer into Ukraine of these extremely challenging swine diseases. Samples were collected and tested at SSRILDVSE using PCR and ELISA. Additionally, scientists performed ASFV-amplicon-based sequencing of 10 samples from swine and wild boar using the MinION sequencing device. A detailed protocol for amplicon-based sequencing of ASFV using MinION platform was produced. The project demonstrated the feasibility of using portable sequencing for ASFV and the integration of GIS. Sequence data analyses of 12 samples suggested ASFV linkage to a Malawi strain of the virus, which will require confirmation by Illumina sequencing.

TO4 Veterinary TAP-6: AWARD FINANCIAL SUMMARY (BTRIC SUPPORT ONLY)<sup>1</sup>

Effective Period	Month Day Year-Month Day Year
	1 September 2016 – 31 August 2017
Estimate total direct cost of the project (US \$)	\$132,000
<i>Including:</i>	
Remuneration to FSU participants	\$ 0
Equipment, materials and supplies including shipping	\$ 97,500
Other Direct Costs (services and subcontracts)	\$ 25,000
Travel	\$ 9,500
Overhead for Ukrainian organizations participating on the project	\$ 0

<sup>1</sup>Direct costs exclude IC indirect costs and potential award fee.



## Evidence of Ukrainian interest in obtaining equipment and means of delivery aimed at using biological agents and toxins in hostile purposes or in armed conflicts



Date: 2021/12/15  
Document №: 211215-UKR-MTC-GNR/48

**Subject** : Baykar Reply to The State Export Control Service of Ukraine Requests About MS-500V-02ST  
**References** :

**To: Motor-Sich JSC, 15, Motorostroiteley Avenue Zaporozhye, 69068, Ukraine**  
Vyacheslav Shuklin  
Senior Contract Engineer

Dear Mr. Shuklin

Baykar would like to express its sincere respect to your company for continuous support.

You may see Baykar reply to The State Export Control Service of Ukraine requests as follows in bold letters:

Государственная служба экспортного контроля Украины просит предоставить следующую информацию про базовый БПЛА:	The State Export Control Service of Ukraine requests you to provide the following information on the basic UAV:
1. Название БПЛА? <b>- БПЛА Bayraktar Akinci</b>	1. UAV name. <b>- Bayraktar Akinci UAV</b>
2. Сфера применения БПЛА? <b>- Двухмоторный самолет с неподвижным крылом</b>	2. UAV scope. <b>- Twin engine fixed wing aircraft</b>
3. Осуществляет контролируемый полет за пределами прямого "естественного видения оператора"? <b>- Да</b>	3. Does the UAV operational mode foresee the capability to be controlled out of the "direct vision range" of the operator? <b>- Yes</b>
4. Максимальная продолжительность полета БПЛА? <b>- 24 часа</b>	4. Maximum duration of a UAV flight <b>- 24 hour</b>
5. Предназначен взлетать и осуществлять полет при порывах ветра 46,3 км/ч (25 узлов) или больше? <b>- Нет</b>	5. Is the UAV designed to take off and perform stable controlled flight in wind gusts of 46.3 km / h (25 knots) or more? <b>- No</b>
6. Способен ли достигать дальность полета 300 км?	6. Is the UAV capable of flying to distances of 300 km?

Baykar Makina San. Tic. A.Ş.

Address: Orhangazi Mah. Hadimköy-Istanbul Cad. No:258 Esenyurt /Istanbul  
Tel: +90 212 867 0900 | Fax: +90 212 867 0949  
www.baykartelence.com

To «Motor-Sich»

Is there a system/mechanism of spraying aerosols with a capacity of more than 20 liters?

UAV name: Bayraktar Akinci

- Нет, в зависимости от прямой видимости и идеальных погодных условий иногда БПЛА может преодолевать расстояние до 300 км, используя 1 наземный терминал передачи данных.	-No, depending on LOS and ideal weather conditions sometimes UAV can go up to 300km by using 1 ground data terminal.
7. Имеется функция автономно осуществлять управление полетом и навигацией? <b>-Да</b>	7. Does the UAV have a function of autonomous flight and navigation control? <b>-Yes</b>
8. Имеется функция осуществлять управляемый полет вне границ зоны прямой видимости при участии человека-оператора? <b>-Да</b>	8. Does the UAV foresee the capability to be controlled out of the "direct vision range" of the operator with the help of a human operator? <b>-Yes</b>
9. Имеется система/механизм распыления аэрозолей емкостью свыше 20л? <b>-Нет</b>	9. Is the UAV equipped a system / mechanism for spraying aerosols with a capacity of more than 20 liters? <b>-No.</b>
10. Какую максимальную полезную нагрузку (кг) и дальность полета (км) способен доставить БПЛА? <b>-Максимальная полезная нагрузка: 3000фунт. Дальность полета: как указано в пункте 6.</b>	10. What is the maximum payload (kg) and flight range (km) that the UAV can deliver? <b>- Maximum payload: 3000lb Flight range: As mentioned in item 6.</b>

We are looking forward to our continued close cooperation

Best regards,

Mustafa KÖŞOĞLU

Coordinator / Vice General Manager

Baykar Makina San. Tic. A.Ş.

Address: Orhangazi Mah. Hadimköy-Istanbul Cad. No:258 Esenyurt /Istanbul  
Tel: +90 212 867 0900 | Fax: +90 212 867 0949  
www.baykartelence.com